SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the FirmBusiness Wire • 04/01/21
CytoDyn files new protocol with FDA for four doses of leronlimab for critically ill coronavirus patientsProactive Investors • 04/01/21
CYDY Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against CytoDyn, Inc. (CYDY); Lead Plaintiff Deadline is May 17, 2021Newsfile Corp • 04/01/21
CytoDyn to Hold Webcast on April 6 to Provide a Full Update on Its ActivitiesGlobeNewsWire • 04/01/21
CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial WiGlobeNewsWire • 04/01/21
CYDY BREAKING NOTICE: ROSEN, A LEADING LAW FIRM, Encourages CytoDyn Inc. Investors with Losses to Secure Counsel Before Important Deadline – CYDYBusiness Wire • 03/31/21
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for CytoDyn Inc. Investors in Securities Fraud Class Action LawsuitPRNewsWire • 03/30/21
CytoDyn's leronlimab decreases mortality by 82% among critically ill coronavirus patients after two weeks in CD12 trialProactive Investors • 03/30/21
CytoDyn's Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 PatientsGlobeNewsWire • 03/30/21
CytoDyn says the Philippines FDA approves the use of leronlimab to treat a COVID-19 patientProactive Investors • 03/29/21
Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. (CYDY)Newsfile Corp • 03/29/21
Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO; Case Study Published in Journal of Translational AutoimmunityGlobeNewsWire • 03/29/21
The Philippines FDA Approves the Use of Leronlimab to Treat a COVID-19 PatientGlobeNewsWire • 03/29/21
Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds CYDY Investors for Securities Fraud Class Action LawsuitNewsfile Corp • 03/26/21
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. - CYDYNewsfile Corp • 03/22/21
CYDY INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against CytoDyn, Inc.PRNewsWire • 03/22/21
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc.Business Wire • 03/21/21
CYDY Class Action Alert: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against CytoDyn Inc.PRNewsWire • 03/20/21
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of CytoDyn, Inc. (CYDY) InvestorsBusiness Wire • 03/19/21
Shareholder Alert: Robbins LLP is Investigating CytoDyn Inc. (CYDY) on Behalf of ShareholdersBusiness Wire • 03/19/21
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of CytoDyn, Inc. (CYDY) InvestorsBusiness Wire • 03/19/21
CYTODYN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against CytoDyn, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 03/19/21
Notice of Lead Plaintiff Deadline for Shareholders in the CytoDyn, Inc. Class Action LawsuitBusiness Wire • 03/18/21
CYDY Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies CytoDyn, Inc. Investors of Class Action and Encourages Shareholders to Contact the FirmPRNewsWire • 03/18/21
